Jump Financial LLC Trims Stock Position in DaVita Inc. (NYSE:DVA)

Jump Financial LLC trimmed its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 78.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,849 shares of the company's stock after selling 17,262 shares during the quarter. Jump Financial LLC's holdings in DaVita were worth $725,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. grew its holdings in shares of DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after buying an additional 275,284 shares in the last quarter. Amundi grew its holdings in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. Bridgewater Associates LP grew its holdings in shares of DaVita by 298.4% during the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after buying an additional 179,744 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of DaVita by 256.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock worth $24,301,000 after buying an additional 116,758 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after acquiring an additional 92,014 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Up 0.8 %

DaVita stock traded up $1.08 during trading on Monday, reaching $140.64. The stock had a trading volume of 587,734 shares, compared to its average volume of 840,706. DaVita Inc. has a 52-week low of $131.27 and a 52-week high of $179.60. The business has a 50 day moving average price of $146.22 and a 200 day moving average price of $155.10. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a market cap of $11.25 billion, a PE ratio of 13.09, a P/E/G ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

DVA has been the topic of several recent research reports. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.